OOIR: Observatory of International Research

Papers

(The median citation count of Therapeutic Advances in Hematology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Monocyte or white blood cell counts and β₂ microglobulin predict the durable efficacy of daratumumab with lenalidomide	31
Brain iron content and cognitive function in patients with β-thalassemia	29
BEST study: one-year descriptive follow-up of bevacizumab treatment in hereditary haemorrhagic telangiectasia post-BABH interventional study	29
Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine	28
Effective engraftment via granulocyte transfusion in pre-engraftment febrile neutropenia following allogeneic hematopoietic stem cell transplantation: granulocyte transfusion as bridge therapy	25
Prognostic impact of IL7R mutations on acute myeloid leukemia	25
The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria	24
A comparison of the effect of three different comorbidity indices on overall survival in patients with chronic myeloid leukemia	22
Macrofocal multiple myeloma in the era of novel agents in China	21
Successful maintenance of a sustained molecular response in CML patients receiving low-dose tyrosine kinase inhibitors	20
Treatment of multiple myeloma: What is the impact on T-cell function?	20
Outcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose methotrexate and R-CHOP: a single-cente	19
Role of abatacept in the prevention of graft-versus-host disease: current perspectives	17
Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes	16
Comparison of eltrombopag and avatrombopag in the treatment of refractory/relapsed aplastic anemia: a single-center retrospective study in China	16
Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma	15
Real-world usage and effectiveness of recombinant factor IX Fc in haemophilia B from the B-SURE study in France	15
Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: post hoc analysis of phase III	14
Safety and efficacy of luspatercept in treating anemia associated with myelodysplastic syndrome with ring sideroblasts in Asian patients who require red blood cell transfusions: a phase II bridging st	14
The role of surveillance computed tomography in patients with follicular lymphoma	14
Efficacy and safety of anti-CD38 monoclonal antibodies-based therapy versus standard therapy in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis	13
Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review	13
Thanks to Reviewers	13
How to translate and implement the current science of gene therapy into haemophilia care?	13
Successful rechallenge with Erwinia chrysanthemi asparaginase after pegaspargase-induced hypertriglyceridemia: a case report	12

Histamine dihydrochloride and low-dose interleukin-2 in an emerging landscape of relapse prevention in acute myeloid leukemia	12
Advancements in minimal residual disease detection: a practical approach using single-cell droplet PCR for comprehensive monitoring in hematological malignancy	12
Cardiovascular-specific mortality among multiple myeloma patients: a population-based study	11
Anemia is associated with long-term exposure to PM_2.5 and its components: a large population-based study in Southwest China	11
Mantle cell lymphoma management trends and novel agents: where are we going?	11
Association of CVAI, LAP and SMI with risk of haematological toxicity after immunochemotherapy in patients with DLBCL: a retrospective study	10
A systematic review and meta-analysis of carfilzomib-associated thrombocytopenia as an adverse event in patients with multiple myeloma	10
The efficacy and safety of asciminib treatment in patients with chronic myeloid leukemia as a second-line or beyond second-line treatment: a systematic review and meta-analysis	10
Use and positioning of fostamatinib in the management of primary chronic immune thrombocytopenia: an Italian expert opinion	10
A new beginning: can omidubicel emerge as the next, viable alternative donor source?	9
Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia	9
Assessment of risk factors for acute graft-versus-host disease post-hematopoietic stem cell transplantation: a retrospective study based on a proportional odds model using a nonlinear mixed-eff	9
Calculated haemorheological profile and laboratory parameters in new diagnosed multiple myeloma patients: retrospective analysis according to survival	9
Toxicity management strategies for next-generation novel therapeutics in multiple myeloma	9
Non-invasive prenatal testing for fetal Ss, Kidd, and CTL2 blood group prediction by multiplex digital droplet PCR	9
Corrigendum to “Real-world use of recombinant porcine sequence factor VIII in the treatment of acquired hemophilia A: EU PASS”	9
Interferons in the treatment of myeloproliferative neoplasms	9
Prognostic significance of MRD and its correlation with arsenic concentration in pediatric acute promyelocytic leukemia: a retrospective study by SCCLG-APL group	8
Superior survival outcome of blinatumomab compared with conventional chemotherapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia: a propensity score–match	8
Circulating HMGB1 is increased in myelodysplastic syndrome but not in other bone marrow failure syndromes: proof-of-concept cross-sectional study	8
Between Charybdis and Scylla—an Odyssey in AL amyloidosis: insights and learnings from a narrative review and case report series	8
Efficacy and safety of venetoclax-based regimens for the treatment of relapsed/refractory multiple myeloma: a systemic review and meta-analysis	8
Single-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia	8
Efficacy of complement inhibitors for patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis	8
Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors	8
Current state of CAR-T therapy for T-cell malignancies	7
Demographics, clinical characteristics, and real-world treatment patterns among patients with beta-thalassemia: a retrospective medical record abstraction study	7
CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma	7
Avatrombopag treatment response in patients with immune thrombocytopenia: the REAL-AVA 1.0 study	7
Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry	7
Application and investigation of thrombopoiesis-stimulating agents in the treatment of thrombocytopenia	7
Efficacy of therapeutic strategies on thrombocytopenia after hematopoietic stem cell transplantation—an evidence-based meta-analysis	7
Significance of whole-blood EBV DNA status in T/NK-cell lymphoma-associated hemophagocytic lymphohistiocytosis: a single-center retrospective analysis	6
Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study	6
Predicting cytomegalovirus infection and graft-versus-host disease using QuantiFERON-CMV and Monitor in pediatric transplants: a proof-of-concept study	6
Risk factors and prognosis of thrombocytopenia in people living with HIV/AIDS	6
Antihuman T lymphocyte porcine immunoglobulin combined with cyclosporine as first-line immunosuppressive therapy for severe aplastic anemia in China: a large single-center, 10-year retrospective study	6
Treatment of multiple myeloma with selinexor: a review	5
Research advances on short-chain fatty acids in gastrointestinal acute graft-versus-host disease	5
Development of a nomogram to predict the risk of secondary failure of platelet recovery in patients with β-thalassemia major after hematopoietic stem cell transplantation: a retrospective study	5
Outpatient allogeneic hematopoietic stem-cell transplantation: a review	5
Is less more? Intravenous immunoglobulin for pediatric immune thrombocytopenia	5
Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease: final results from the phase II SOLACE-adults study	5
Relapsed/refractory pure red cell aplasia in chronic lymphocytic leukemia successfully treated with acalabrutinib: a case report and review of the literature	5
A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)	5
Advancing the standard: venetoclax combined with intensive induction and consolidation therapy for acute myeloid leukemia	5
Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A: post hoc subanalysis of the randomized, phase 3 PROPEL	5
Avatrombopag for the salvage treatment of platelet transfusion refractoriness	5
Safety of venetoclax in real-world experience: data from the French national database of pharmacovigilance through all indications in hematological malignancies over 5 years	5
Mechanisms of resistance to histone deacetylase inhibitors in acute leukemia	5

Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria	5
Prednisone plus IVIg compared with prednisone or IVIg for immune thrombocytopenia in pregnancy: a national retrospective cohort study	4
Durable outcomes of double cord blood transplantation in adults with acute lymphoblastic leukemia: high-risk features for early and long-term mortality	4
Diagnosis and management of multiple myeloma during pregnancy: case report, review of the literature, and an update on current treatments	4
Design of an international, phase IV, open-label study of simoctocog alfa in women/girls with hemophilia A undergoing surgery (NuDIMENSION)	4
Progress and prospect of ASCT combined with CAR-T therapy in the treatment of multiple myeloma	4
Major cardiac surgery with recombinant FIX Fc fusion protein replacement in hemophilia B: a case report	4
Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: a living systematic review on comparative studies	4
Recent advances in CAR-T therapy for the treatment of acute myeloid leukemia	4
The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia	4
An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment	4
An occurrence of eosinophilic folliculitis and alopecia associated with a sustained complete response to mogamulizumab in Sézary syndrome: a case report	4
Vedolizumab for second-line treatment of steroid-refractory gastrointestinal late acute graft-versus-host disease	4
Next-generation sequencing of circulating tumor DNA in cerebrospinal fluid for detecting gene mutations in central nervous system lymphoma patients	3
Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma	3
Experience in the management of patients with HTLV-1 positive adult T-cell leukemia/lymphoma in a Latin American center	3
Cost-effectiveness analysis of axicabtagene ciloleucel as a second-line treatment for diffuse large B-cell lymphoma in China and the United States	3
The efficacy and safety of third-party umbilical blood/umbilical cord mesenchymal stem cell assisted related haploid hematopoietic stem cell transplantation in pediatric patients with acute leukemia:	3
Improved survival outcomes with anakinra over etoposide-based therapies for the management of adults with hemophagocytic lymphohistiocytosis: a retrospective multicenter research network study	3
Clinical outcomes of high-risk patients with polycythemia vera after suboptimal response to first-line therapy who switched to ruxolitinib versus nonswitchers: results from the PV-Switch study	3
MYD88^L265P and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy	3
Infrastructural considerations of implementing gene therapy for hemophilia in the Nordic context	3
Iron overload status in patients with non-transfusion-dependent thalassemia in China	3
Systematic literature review of the indirect costs and humanistic burden of β-thalassemia	3
Effect of BCR::ABL1 transcript type and droplet digital polymerase chain reaction on successful treatment-free remission in chronic myeloid leukemia patients who discontinued tyrosine kinase in	3
Clinical features and treatment of newly diagnosed multiple myeloma with secondary myelofibrosis: a retrospective study	3
Real-world use of recombinant porcine sequence factor VIII in the treatment of acquired hemophilia A: EU PASS	3
When idiopathic multicentric Castleman disease meets COVID-19: a multicenter retrospective study from China	2
A nomogram based on InLDH and InNLR for predicting disseminated intravascular coagulation in patients with heat stroke	2
Efficacy and safety of avatrombopag in the treatment of chemotherapy-induced thrombocytopenia in children with acute lymphoblastic leukemia: a single-center retrospective study	2
Cost-effectiveness of acalabrutinib monotherapy or with obinutuzumab versus chemoimmunotherapy for untreated chronic lymphocytic leukemia in China	2
A phase I trial of pevonedistat in combination with ruxolitinib for the treatment of myelofibrosis	2
Real-world patient characteristics and treatment patterns of polycythemia vera in Taiwan between 2016 and 2017: a nationwide cross-sectional study	2
Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib	2
Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from	2
Gene therapy in haemophilia: literature review and regional perspectives for Turkey	2
Outcomes and management of invasive procedures in participants with hemophilia A post gene therapy: a post hoc analysis of the GENEr8-1 phase III trial	2
Efficacy of emicizumab in patients with severe haemophilia A without factor VIII inhibitors in Germany: evaluation of real-life data documented by the smart medication eDiary	2
Recent advances of CAR-T cells in acute myeloid leukemia	2
Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study	2
A systematic literature review of 74 Chinese blastic plasmacytoid dendritic cell neoplasm patients	2
Acquired von Willebrand syndrome secondary to monoclonal gammopathy: a single-center case series	2
Total body irradiation-based myeloablative conditioning for acute lymphoblastic leukaemia patients undergoing allogeneic haematopoietic stem cell transplantation: the best way to prevent relapse in a	2
The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma	2
Recent advances in immunotherapy for B-cell non-Hodgkin lymphoma and multiple myeloma	2
Genetic lesions and targeted therapy in Hodgkin lymphoma	2
The clinical utility and prognostic value of next-generation sequencing for measurable residual disease assessment in acute myeloid leukemia	2
Improvement in pain-related quality of life in patients with hemophilia A treated with rFVIIIFc individualized prophylaxis: post hoc analysis from the A-LONG study	2
Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study	2
Down syndrome-associated leukaemias: current evidence and challenges	2